Abstract:All- trans -retinoic acid (ATRA)-based differentiation therapy of acute promyelocytic leukemia (APL) represents one of the most clinically effective examples of precision medicine and the first example of targeted oncoprotein degradation. The success of ATRA in APL, however, remains to be translated to non-APL acute myeloid leukemia (AML). We previously showed that aberrant histone modifications, including histone H3 lysine 4 (H3K4) and lysine 27 (H3K27) methylation, were associated with this lack of response and that epigenetic therapy with small molecule inhibitors of the H3K4 demethylase LSD1/KDM1A could reprogram AML cells to respond to ATRA. Serving as the enzymatic component of Polycomb Repressive Complex 2, EZH2/KMT6A methyltransferase plays a critical role in normal hematopoiesis by affecting the balance between self-renewal and differentiation. The canonical function of EZH2 is methylation of H3K27, although important non-canonical roles have recently been described. EZH2 mutation or deregulated expression has been conclusively demonstrated in the pathogenesis of AML and response to treatment, thus making it an attractive therapeutic target. In this study, we therefore investigated whether inhibition of EZH2 might also improve the response of non-APL AML cells to ATRA-based therapy. We focused on GSK-343, a pyridone-containing S-adenosyl-L-methionine cofactor-competitive EZH2 inhibitor that is representative of its class, and HKMTI-1-005, a substrate-competitive dual inhibitor targeting EZH2 and the closely related G9A/GLP H3K9 methyltransferases. We found that treatment with HKMTI-1-005 phenocopied EZH2 knockdown and was more effective in inducing differentiation than GSK-343, despite the efficacy of GSK-343 in terms of abolishing H3K27 trimethylation. Furthermore, transcriptomic analysis revealed that in contrast to treatment with GSK-343, HKMTI-1-005 upregulated the expression of differentiation pathway genes with and without ATRA, while downregulating genes associated with a hematopoietic stem cell phenotype. These results pointed to a non-canonical role for EZH2, which was supported by the finding that EZH2 associates with the master regulator of myeloid differentiation, RARα, in an ATRA-dependent manner that was enhanced by HKMTI-1-005, possibly playing a role in co-regulator complex exchange during transcriptional activation. In summary, our results strongly suggest that addition of HKMTI-1-005 to ATRA is a new therapeutic approach against AML that warrants further investigation.

Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Co‐Targeting C‐myc and Bcl‐2 by Oral Small Molecule Combination of WBC100 and Venetoclax Effectively Controls Acute Myeloid Leukemia in Preclinical Models

CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells

Single-cell multiomics reveals a gene regulatory circuit promoting leukemia cell differentiation

Restoration Of Ccaat Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block And All-Trans Retinoic Acid Resistance In Human Acute Promyelocytic Leukemia Nb4-R1 Cells

C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells

Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2.

The CDK4/6 inhibitor Palbociclib synergizes with ATRA to induce differentiation in AML

HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms

Increased Release of Microvesicles Containing Mitochondria is Associated with the Myeloid Differentiation of AML-M5 Leukaemia Cells.

Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.

3D back shape in normal young adults.

Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells

Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199

The HER2 Inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by Activating MEK/ERK Mediated RARα/STAT1 Axis

[Presentation of statistical data in nursing care. 3--Bar graphs: providing service information].

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia

BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph+ Chronic Myeloid Leukemia

Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4

CEBPG promotes acute myeloid leukemia progression by enhancing EIF4EBP1